Administration of human urinary colony stimulating factor after bone marrow transplantation.
A phase II study of the use of colony stimulating factor derived from human urine (CSF-HU) was performed after bone marrow transplantation (BMT). Steady and rapid recovery of leukocyte and granulocyte numbers was observed. In most patients who received CSF-HU from day 1, leukocyte numbers started to increase on day 6 and monocytes and granulocytes on day 11. Significant differences in the days to recovery of leukocytes over 1 x 10(9)/l and of granulocytes over 0.5 x 10(9)/l were observed in comparison with non-randomized control patients. In some patients in whom recovery of leukocytes was delayed, CSF also seemed to be effective in increasing leukocyte numbers from 8 days after the start of administration. There was no significant difference in the rate of relapse of leukemia between the two groups. CSF-HU seems very promising as a treatment of patients after BMT by shortening the period of leukopenia or granulocytopenia.
D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D003115:Colony-Stimulating Factors / Q000008:administration & dosage* / Q000009:adverse effects / Q000652:urine; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006084:Graft Rejection; D006086:Graft vs Host Disease / Q000209:etiology; D006801:Humans; D007223:Infant; D007262:Infusions, Intravenous; D007938:Leukemia / Q000628:therapy; D007958:Leukocyte Count / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D012008:Recurrence
D003115:Colony-Stimulating Factors